News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
243 Results
Type
Article (2)
Company Profile (1)
Press Release (240)
Section
Business (39)
Drug Development (33)
FDA (28)
Job Trends (5)
News (108)
Policy (12)
Tag
2027 BioMidwest Standard (1)
2027 Bio NC Standard (1)
2027 Genetown Standard (1)
2027 Pharm Country Standard (1)
Academia (1)
ADA (2)
Alliances (13)
Approvals (31)
Best Places to Work (5)
Cardiovascular disease (6)
Clinical research (38)
Data (12)
Diabetes (7)
Drug pricing (1)
Earnings (7)
Events (25)
FDA (33)
GLP-1 (5)
Healthcare (21)
Indications (2)
Job creations (3)
Legal (3)
MASH (1)
Metabolic disorders (11)
NextGen: Class of 2026 (1)
Obesity (6)
People (14)
Pharmaceutical (1)
Phase 2 (6)
Phase 3 (28)
Pipeline (15)
Postmarket research (5)
Real estate (4)
Regulatory (14)
Weight loss (4)
Women's health (1)
Date
Last 30 days (1)
Last 365 days (18)
2026 (12)
2025 (11)
2024 (10)
2023 (5)
2022 (1)
2021 (8)
2020 (11)
2019 (15)
2018 (8)
2017 (15)
2016 (27)
2015 (6)
2014 (16)
2013 (17)
2012 (13)
2011 (12)
2010 (23)
Location
Europe (22)
New Jersey (29)
New York (1)
United States (30)
243 Results for "novonordiskus".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Novo Nordisk advances cardiometabolic pipeline with new data featuring CagriSema and zenagamtide at the American Diabetes Association’s 2026 Scientific Sessions
May 27, 2026
·
12 min read
Press Releases
Novo Nordisk announces significant reduction in US list price for Wegovy®, Ozempic®, and Rybelsus® (semaglutide medicines), building on continued efforts to expand access
February 24, 2026
·
15 min read
Press Releases
Novo Nordisk to showcase new data across its hemophilia portfolio at the ISTH Congress 2026, featuring investigational denecimig
June 26, 2026
·
7 min read
Press Releases
Novo Nordisk’s CagriSema 2.4 mg / 2.4 mg demonstrated significant reduction in HbA1c and weight across multiple studies in the REIMAGINE program presented at ADA 2026
June 8, 2026
·
12 min read
Press Releases
Wegovy® pill prescriptions surpass 3 million, 1 filled roughly every 5 seconds, bringing GLP-1 therapy to people with obesity previously untreated, while Novo Nordisk unveils new data at ADA 2026
June 8, 2026
·
12 min read
Press Releases
Novo Nordisk to present new data on Wegovy® across a wide range of cardiometabolic conditions at the American Diabetes Association’s 2026 Scientific Sessions
June 8, 2026
·
13 min read
Press Releases
Novo Nordisk’s investigational zenagamtide shows significant A1C reductions with up to 14.6% weight loss in adults with type 2 diabetes--presented at ADA 2026
June 7, 2026
·
7 min read
Press Releases
Denecimig (Mim8) significantly reduced annualized bleeding rate in people with hemophilia A, regardless of inhibitor status, in phase 3 data published in NEJM
April 29, 2026
·
9 min read
Press Releases
Novo Nordisk’s Wegovy® HD available now nationwide
April 7, 2026
·
13 min read
Press Releases
Wegovy® pill demonstrated greater weight loss than orforglipron and lower odds of stopping medication due to side effects in a new indirect comparison to be presented at Obesity Medicine Association 2026
April 2, 2026
·
10 min read
1 of 25
Next
